» Articles » PMID: 30319959

PH-Responsive Cross-Linked Low Molecular Weight Polyethylenimine As an Efficient Gene Vector for Delivery of Plasmid DNA Encoding Anti-VEGF-shRNA for Tumor Treatment

Overview
Journal Front Oncol
Specialty Oncology
Date 2018 Oct 16
PMID 30319959
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

RNA interference (RNAi) is a biological process through which gene expression can be inhibited by RNA molecules with high selectivity and specificity, providing a promising tool for tumor treatment. Two types of molecules are often applied to inactivate target gene expression: synthetic double stranded small interfering RNA (siRNA) and plasmid DNA encoding short hairpin RNA (shRNA). Vectors with high transfection efficiency and low toxicity are essential for the delivery of siRNA and shRNA. In this study, TDAPEI, the synthetic derivative of low-molecular-weight polyethylenimine (PEI), was cross-linked with imine bonds by the conjugation of branched PEI (1.8 kDa) and 2,5-thiophenedicarboxaldehyde (TDA). This biodegradable cationic polymer was utilized as the vector for the delivery of plasmid DNA expressing anti-VEGF-shRNA. Compared to PEI (25 kDa), TDAPEI had a better performance since experimental results suggest its higher transfection efficiency as well as lower toxicity both in cell and animal studies. TDAPEI did not stimulate innate immune response, which is a significant factor that should be considered in vector design for gene delivery. All the results suggested that TDAPEI delivering anti-VEGF-shRNA may provide a promising method for tumor treatment.

Citing Articles

Enhanced Targeted Delivery of Minocycline via Transferrin Conjugated Albumin Nanoparticle Improves Neuroprotection in a Blast Traumatic Brain Injury Model.

Perumal V, Ravula A, Agas A, Gosain A, Aravind A, Sivakumar P Brain Sci. 2023; 13(3).

PMID: 36979212 PMC: 10046830. DOI: 10.3390/brainsci13030402.


A Low-Molecular-Weight Polyethylenimine/pDNA-VEGF Polyplex System Constructed in a One-Pot Manner for Hindlimb Ischemia Therapy.

Guo X, Yuan Z, Xu Y, Zhao X, Fang Z, Yuan W Pharmaceutics. 2019; 11(4).

PMID: 30965617 PMC: 6523750. DOI: 10.3390/pharmaceutics11040171.

References
1.
Mailliez A, Baldini C, Van J, Servent V, Mallet Y, Bonneterre J . Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer. 2010; 103(6):772-5. PMC: 2966623. DOI: 10.1038/sj.bjc.6605828. View

2.
Cruz P, Mueller C, Cossette T, Golant A, Tang Q, Beattie S . In vivo post-transcriptional gene silencing of alpha-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab Invest. 2007; 87(9):893-902. DOI: 10.1038/labinvest.3700629. View

3.
Thomay A, Nagorney D, Cohen S, Sigurdson E, Truty M, Burtness B . Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer. J Gastrointest Surg. 2013; 18(1):69-74. DOI: 10.1007/s11605-013-2329-8. View

4.
Xi H, Zhang K, Li J, Cui J, Gao Y, Wei B . RNAi-mediated inhibition of Lgr5 leads to decreased angiogenesis in gastric cancer. Oncotarget. 2017; 8(19):31581-31591. PMC: 5458231. DOI: 10.18632/oncotarget.15770. View

5.
Tripathy S, Vinokour E, McMahon K, Volpert O, Thaxton C . High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis. Part Part Syst Charact. 2014; 31(11):1141-1150. PMC: 4228967. DOI: 10.1002/ppsc.201400036. View